INTRODUCTION
The ability of 1,3-diallylurea to retard transplanted tumors was observed in the course of investigating the iÂ»tential antitumor activity of a larger number of chemicals in an animal tumor spectrum. Previous studies failed to reveal the tumorinhibitory activity of 1,3-diallylurea against Sarcoma 180 (4), but in spontaneous tumors of S\YR and C3H mice, this chemical produced retardation (11) .
The purj>ose of the present study was to test the activity of 1,3-diallylurea against the present spectrum of 1 rat and 8 mouse tumors and to compare its activity with 12 related compounds.
MATERIALS AND METHODS
The toxicity of allylureas was examined in tumor-free CHKRFi female mice. A wide range of single or repeated doses was ad ministered, each dose to a group of 30 mice. Treated mice were observed for 3 weeks, at the end of which mortality was plotted against the logarithm of dose on probability pa]>er and the lethal dose for 50% of the animals (LD50) w-ascalculated by the method of Miller and Tainter (5) .
Tumors of the present s|>ectrum included Melanoma B16, 1Supported in part by Contract SA-43-ph-2445from the Cancer Chemotherapy National Service Center, National Cancer Insti tute, USPHS and in part by Grant CA-08748 from the National Cancer Institute.
Received (1, 6, 9) . Briefly, fragments of solid tumors were inoculated s.c. with a trocar, and suspensions of Ehrlich ascites cells were injected i.p. Treatment started the day after inoculation in all tumors except Carcinoma C1025 and Ridgway osteogenic sarcoma, in which it was started 5 days after inocula tion. Chemicals were injected once daily for 7 days. Each dose level was given to 5 mice or rats; the control groups consisted of 10 animals treated with the vehicle, in which the drugs were dissolved or suspended. Parameters of tumor growth were as follows: average tumor diameter in cm at the end of therapy and 1 week thereafter for solid tumors; total packed cell volume in ml for Ehrlieh ascites tumor at the end of therapy; and mean survival time for Mecca lymphosarcoma. The effects of therapy were evaluated by the treated/control (T/C) values for the tumor-growth parameters in both treated and control animals. Those for treated tumors were compared with previously established acceptance values for control tumors. Significant retardation was estimated as follows: for solid tumors and Ehrlich ascites tumor, T/C values smaller than the minimal acceptance T/C value; and for Mecca lymphosarcoma, values greater than the maximal T/C accept ance value.
The evaluation of drug toxicity was based on mortality and average weight change in gm of tumor-bearing animals. Maximal doses causing 20 % mortality or less at the end of therapy or 40% mortality or less 1 week thereafter were considered maximal tolerated doses. At the end of therapy they caused an average weight change of 15% or less in treated mice and allowed treated rats to gain 5 gm or more of body weight.
Bioassay of the Ridgway osteogenic sarcoma treated with 1,3-diallylurea in vitro was performed by an adaptation of the previ ously described technic (8) . Fragments of the tumor were incu bated at 4Â°C or 37Â°C for 4 or 24 hr in a solution of 1,3-diallylurea in saline or in saline alone. Incubated fragments were inoculated into the axillary region of CHKRFi mice, the diallylurea-treated fragments on one side and the saline-treated ones on the other. The number of tumors growing at each side 2 and 4 weeks after inoculation was recorded. Growing tumors did not affect the 
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average weight change or mortality during the 2nd and 3rd weeks. During the 4th week some mice died.
Chemicals tested in the tumor si>ectrum and their structural formulas and sources are listed in Table 1 
1,3-dibenzylurea, and 1,3-dimethylolurea were suspended in 0.5'V solution of carboxymethylcellulose in saline, and the rest were dissolved in saline. When supplies were limited, chemicals were tested only in selected tumors.
RESULTS
The LD60 of 1,3-diallylurea, administered i.p. to tumor-free CHKKFi female mice, was similar to the LD60 of monoallylurea and significantly higher (P < 0.01) than the LD50 for 1,1-diallvlurea (Table 2 ). Repeated i.p. doses of each of the 3 allylureas were less well tolerated than single doses. 1,3-Diallylurea administered orally was less toxic than when given by s.c. or i.p. routes. Table 3 shows the effect of the maximal tolerated dose of 1,3-diallylurea on tumor-bearing animals. Average values of tumor-growth indices and of average weight changes calculated from at least 2 or 3 replications are presented, as well as the mortality. Maximal tolerated dose of 1,3-diallylurea in the majority of tumors varied from 125 to 250 mg/kg/day for 7 injections, administered once daily. Carcinoma K0771 debilitated its hosts to a greater extent than Melanoma BIO or Sarcoma T241. All 3 of these tumors were grown in C57HL/6 male mice. The maximal tolerated dose of 1,3-diallylurea was 62.5 mg/kg/ day in mice with Carcinoma K0771. On the other hand, rats tolerated this chemical better than the mice, and the maximal tolerated dose was 500 mg/kg/day. Significant retardation of Carcinoma C1025 and Ridgway osteogenic sarcoma was observed both at the end of therapy and 1 week thereafter. Borderline antitumor effects were obtained at the end of therapy in Mecca lymphosareoma and Walker Carcinosarcoma 256 and 1 week thereafter in Carcinoma K0771. Other tumors were not significantly retarded by the maximal tolerated dose of 1,3-diallylurea. Table 4 shows that similar degrees of retardation in Carcinoma C1025 and Ridgway osteogenic sarcoma were produced by a wide range of nontoxic doses of 1,3-diallylurea. The effective nontoxic i.p. doses ranged from 4 to 125 mg/kg/day in Carci noma C1025 and from 7.8 to 125 mg/kg/day in Ridgway osteo genic sarcoma. Even the highest dose of 250 mg/kg/day did not induce average weight loss greater than about 3090 of that of the controls.
Repeated administration of intermediate doses of 1,3-diallyl urea i.p., s.c., and p.o. for 7 days produced similar degrees of retardation in Carcinoma C1025 and Ridgway osteogenic sarcoma 1 week after the end of therapy (Table 5 ). Oral administration of the highest dose, however, produced toxicity. 0 Results at end of therapy + 1 week. 6 Administration (i.p.) once daily for 7 days, beginning on the 5th day of tumor growth.
hr at 37Â°Cin 0.02-0.5% solutions of 1,3-diallylurea in saline showed diminished transplantability (Table 6 ). At 2 weeks the proportion of growing inocula was significantly lower (P < 0.05) when they were treated with a 0.5 % solution of 1,3-diallylurea prior to implantation than when they were incubated in saline (controls). The difference was not statistically significant at 4 weeks.
1,1-Diallylurea, monoallylurea, and 1,3-diallylthiourea, 3 chemicals related to 1,3-diallylurea, were tested for antitumor activity at maximal tolerated dose in all or in the majority of tumors. Only 1,1-diallylurea retarded any tumor. It significantly retarded K0771 at the end of therapy and 1 week thereafter and produced a borderline effect in Ehrlich ascites tumor. Nine additional ureas (Table 1) substituted on the nitrogen atoms with alkyl groups other than the allyl groups were ineffective when tested at maximal tolerated dose against Ridgway osteogenic sarcoma.
DISCUSSION
The study indicates that 1,3-diallylurea retarded some tumors of the spectrum. Only those substituted ureas with 2 allyl groups exhibited antitumor activity which in turn was more pronounced in the symmetrically substituted 1,3-diallylurea. Replacement of the oxygen with the sulfur atom at the carbon atom of the urea abolished this activity. Such restricted structural specificity is of interest.
The wide range of non toxic doses of 1,3-diallylurea which inhibited Carcinoma C1025 and Ridgway osteogenic sarcoma was not caused by the )X3or solubility of this chemical either in saline or in 0.5% carboxymethylcellulose in saline. Doses higher than 12o mg/kg/day were administered as sus]Â»nsions in carboxymethylcellulose-saline.
Results of the therapy in vivo of these 2 tumors were similar whether the compound was ad ministered i.p., S.C., or p.o. in intermediate doses. The transplant- ' Treated/control. ability of tumor fragments was decreased when they were incu bated in solutions of 1,3-diallylurea.
It was previously rejwrted that 1,1 -diallylurea was inactive against Sarcoma 180 (7) and 1,3-diallylthiourea did not retard either the ascites or solid form of Ehrlich tumor (2) .
Other classes of allyl-substituted chemicals besides diallylureas have been reported to have the capacity to retard animal tumors: diallylamine, mouse Sarcoma 180; diallylmethacrylamide, mouse Carcinoma 755; and Ar,Ar-diallyl-o-aziridinopropionamide, the Dunning rat leukemia (10) . It was suggested that the allyl group is capable of conversion to a cyclic ethylenimmonium ion and acts as a latent alkylating agent.
Allicin, diallylthiosulfinic acid, decreased the transplantability of Ehrlich ascites and Sarcoma 180 ascites cells incubated in an aqueous solution of this chemical, but no antitumor activity was detected in vivo (3) . Allicin also inhibited the succinoxidase activity of rat liver and of some other SH-dependent enzymes (12) . This activity was dependent on the presence of the â€¢â€"SO .Sâ€" grouping in allicin rather than on its allyl groups since diallylsulfide, diallyldisulfide, and diallylsulfoxide did not in hibit succinic oxidase.
